Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for LUPIN
Revenue projections for LUPIN

With Lupin Limited's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 0.00000
forwardPE 22.78436
debtToEquity 31.51300
earningsGrowth 0.37300
revenueGrowth 0.24300
grossMargins 0.70556
operatingMargins 0.26460
trailingEps 101.43000
forwardEps 97.40891

LUPIN's Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
With both earnings and revenue growth showing positive trends, LUPIN is expected to expand its business. This signals a healthy financial trajectory, suggesting that the company is positioned for continued growth and increasing profitability.
LUPIN's positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.
Lupin Limited's forward EPS being less than trailing EPS suggests the company may see a drop in profitability this year. This signals potential financial challenges and a less optimistic outlook for earnings growth.

Price projections:

Price projections for LUPIN
Price projections for LUPIN

Lupin Limited's price projections have gradually increased over time, indicating that analysts are becoming more optimistic about the company's prospects. This suggests confidence in Lupin Limited's ability to achieve future growth.

Recommendation changes over time:

Recommendations trend for LUPIN
Recommendations trend for LUPIN


LUPIN has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view LUPIN as a stable option to park their money and potentially benefit from the company's continued growth and profitability.